Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
Alumis Inc. Common StockNASDAQ: ALMS
Other Non-current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Other non-current liabilities falls 56.9% from a year ago
Other non-current liabilities stood at $239K at the end of Q2 FY2026, down 56.9% from a year earlier and down 20.6% from the prior quarter. Over 3 fiscal years it compounded at -89.6% a year.
Context
- Other non-current liabilities amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Other non-current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current liabilities keeps falling in the next quarterly balance sheet after a -56.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 330K USD
- Year-over-year change
- -59.5%
- 3-year CAGR
- -89.6%
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 330K | -59.5% |
| FY2024 | 2024-12-31 | 814K | -99.8% |
| FY2023 | 2023-12-31 | 377.14M | +30.2% |
| FY2022 | 2022-12-31 | 289.59M | — |
Other Non-current Liabilities vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -56.9% is the 3rd highest of 6, against a peer median of -64.0%.
- Other non-current liabilities amounts to 0.0% of total assets for ALMS, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $17.52M USD | +79.9% | +28.2% | 17.5% | |
| Mar 2026 | $11M USD | -64.0% | -31.8% | 5.5% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €8.11M EUR | — | — | 4.9% |
ALMSAlumis Inc. Common Stock | Jun 2026 | $239K USD | -56.9% | -89.6% | 0.0% |
| Mar 2026 | €36.92K EUR | +0.1% | -0.0% | 0.1% | |
| Mar 2026 | $0 USD | -100.0% | -3.2% | 0.0% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $0 USD | — | — | 0.0% |
| Dec 2025 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ALMS) | — | -64.0% | -1.6% | 0.0% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.